Edgewise Therapeutics/$EWTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Edgewise Therapeutics

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Ticker

$EWTX
Sector
Primary listing

Employees

126

EWTX Metrics

BasicAdvanced
$1.6B
-
-$1.55
0.26
-

What the Analysts think about EWTX

Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.

Bulls say / Bears say

As of April 2025, the company’s pro-forma cash balance surpassed $624 million after raising $188 million in net proceeds, giving Edgewise funding through 2026.
Announced positive top-line results from the Phase 2 CIRRUS-HCM study of EDG-7500, showing significant reductions in left ventricular outflow tract gradient with no major loss of ejection fraction.
Initial results from the Phase 2 FOX study showed sevasemten 10 mg may slow functional decline in Duchenne patients treated with gene therapy, supporting progression to late-stage trials.
The Phase 2 EDG-7500 trial reported two serious atrial fibrillation events requiring cardioversion, leading to a more than 20% drop in the share price and raising FDA safety concerns.
Shares fell 47.7% in a single week, despite positive cardiomyopathy results, highlighting the stock’s high volatility due to safety worries in the CIRRUS-HCM trial.
14% of patients in the trial developed atrial fibrillation, including two serious incidents—investors are nervous about regulatory challenges and competition from rivals such as Cytokinetics, which gained 7.3% as Edgewise stumbled.
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.

EWTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

EWTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EWTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Edgewise Therapeutics stock | $EWTX Share Price | Lightyear